India's health ministry has introduced strict curbs and oversight on stem cell therapy for critical limb ischemia and chronic wounds, citing rampant use despite limited knowledge of safety and efficacy. The regenerative medicine market, including stem cell-based therapy, was valued at ₹7,641 crore in 2024 and is projected to reach ₹4.33 trillion by 2033, according to livemint.com.
The ministry highlighted concerns over the experimental nature of these therapies, noting little evidence to support clinical benefits. The new regulations aim to curb unregulated practices and ensure patient safety. This move follows reports of widespread use of stem cell treatments without adequate scientific backing, prompting the government to enforce tighter controls and monitoring mechanisms.
The Indian regenerative medicine sector has seen rapid growth, but regulatory challenges have persisted due to the experimental status of many therapies. The ministry's decision aligns with global trends emphasizing evidence-based clinical applications and patient protection. The market's projected expansion underscores the importance of balancing innovation with rigorous oversight to prevent misuse and ensure effective treatments.
The new regulatory framework was announced on August 19, 2026, and will require compliance from all clinics and research institutions offering stem cell therapies for critical limb ischemia and chronic wounds, as reported by livemint.com.